A Multicenter, Single-group Phase II Clinical Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of Multiple Subcutaneous Injections of SHR-1703 in Eosinophilic Asthma Patients
Latest Information Update: 11 Jun 2024
At a glance
- Drugs SHR-1703 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 11 Jun 2024 New trial record